



Kroger
Prescription
Plans

2022 Annual KPP Trend Report

4.15% *Overall
Trend*

Low Cost Generics & Clinical Innovation

By maximizing low-cost generics and implementing innovative clinical programs, our clients collectively achieved an industry leading overall trend.

0.17% *Traditional
Drug Spend*

Generic Dispensing Rate 86.3%

- 8.8% Unit Price, -6.5% Utilization, -3.3% Drug Mix

7.34% *Specialty
Drug Spend*

Driving 52.7% of Total Plan Paid

- Specialty 360 Program decreased specialty drug spend by 13.4%
- -2.7% Unit Cost, 1.7% Utilization, 12.9% Drug Mix

800.917.4926

www.kpp-rx.com

Innovative Clinical Programs

Clinical Performance Based Guarantee – Suite of Clinical Programs that We Guarantee Will Lower Your Prescription Drug Spend

Specialty 360 – Dynamic Copay Program that Maximizes Copay Cards to Offset Costly Specialty and Non-Specialty Therapies

OTC Alternative Exclusion Program – Stop Covering Rx Drugs that are Available Over-The-Counter

High-Cost Generic Program – Switch Patients from High-Cost Generic Medication to Lower Cost Alternatives

Reference Based Pricing – Proactively Contains Cost in Select Drug Classes

Top 3 Drug Classes

Inflammatory Diseases

Diabetes

Neoplastic Disease

Forecast

Plaque Psoriasis – Variety of biologic agents on the market and expected in the pipeline, in addition to new advances in precision medicine technology

Diabetes – Anticipate impact with changes in insulin pricing, cap on member cost-share, and emergence of biosimilars.

Inflammatory – Humira will face competition with the introduction of adalimumab biosimilar launches mid-2023.

2023 Kroger Prescription Plans | Confidential Information

The content of this document is CONFIDENTIAL and PROPRIETARY to Kroger Prescription Plans, Inc. and may not be reproduced, transmitted, published, or disclosed without prior written authorization. Kroger Prescription Plans, Inc. maintains the sole and exclusive ownership, right, title, and interest in this document.

2971-040221-9026